VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
P. Moreau, M.A.C. Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, F. Casca, Sandrine Macé, Erwin Singh, M-L. Risse, Thomas G. Martin
Topics & Concepts
MedicineCarfilzomibInternal medicineInterim analysisClinical endpointProgression-free survivalMultiple myelomaOncologyGastroenterologyUrologyLenalidomideRandomized controlled trialOverall survivalMultiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies ResearchCancer Mechanisms and Therapy